Mikhail Lichinitser

22.4k total citations · 8 hit papers
62 papers, 9.9k citations indexed

About

Mikhail Lichinitser is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mikhail Lichinitser has authored 62 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Mikhail Lichinitser's work include Cancer Treatment and Pharmacology (22 papers), HER2/EGFR in Cancer Research (18 papers) and Colorectal Cancer Treatments and Studies (18 papers). Mikhail Lichinitser is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), HER2/EGFR in Cancer Research (18 papers) and Colorectal Cancer Treatments and Studies (18 papers). Mikhail Lichinitser collaborates with scholars based in Russia, United States and Switzerland. Mikhail Lichinitser's co-authors include Werner Scheithauer, Leonard B. Saltz, Eduardo Díaz‐Rubio, Jim Cassidy, Tsai‐Shen Yang, Fernando Rivera, Stephen Clarke, Félix Couture, Sheryl Koski and Arié Figer and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mikhail Lichinitser

61 papers receiving 9.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

2008 2.3k citations Leonard B. Saltz, Stephen Clarke et al. Journal of Clinical Oncology profile →
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

2010 1.1k citations Alison Stopeck, Allan Lipton et al. Journal of Clinical Oncology profile →
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2010 891 citations Luca Gianni, W. Eiermann et al. profile →
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Xavier Pivot, Mikhail Lichinitser et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

2008 652 citations Jim Cassidy, Stephen Clarke et al. Journal of Clinical Oncology profile →
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

2009 582 citations Yoon‐Koo Kang, Won Ki Kang et al. Annals of Oncology profile →
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

2010 453 citations Angelo Di Leo, Guy Jérusalem et al. Journal of Clinical Oncology profile →
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

2010 425 citations Jaffer A. Ajani, W. Rodriguez et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Mikhail Lichinitser

Since Specialization

Citations

This map shows the geographic impact of Mikhail Lichinitser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikhail Lichinitser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikhail Lichinitser more than expected).

Fields of papers citing papers by Mikhail Lichinitser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikhail Lichinitser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikhail Lichinitser. The network helps show where Mikhail Lichinitser may publish in the future.

Co-authorship network of co-authors of Mikhail Lichinitser

This figure shows the co-authorship network connecting the top 25 collaborators of Mikhail Lichinitser. A scholar is included among the top collaborators of Mikhail Lichinitser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikhail Lichinitser. Mikhail Lichinitser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up 2016 ·European Journal of Cancer ·Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin‐Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Sung‐Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, Georg Kunz, S. Falcon, Shou‐Tung Chen, (unknown), Dominik Heinzmann, Mona Shing, Xavier Pivot	58
2	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort 2014 ·The Lancet Oncology ·Luca Gianni, W. Eiermann, Semiglazov Vf, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Dominik Heinzmann, Jutta Steinseifer, Pinuccia Valagussa, José Baselga	356
3	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) 2013 ·The Lancet Oncology ·Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja, Otto Metzger, (unknown), (unknown), István Láng, Andrew Wardley, Mikhail Lichinitser, (unknown), Volkmar Müller, David Dodwell, Richard D. Gelber, Martine Piccart, David Cameron	142
4	Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer 2013 ·Annals of Oncology ·Brian M. Wolpin, Eileen M. O’Reilly, Yoo-Joung Ko, Lawrence S. Blaszkowsky, Mark U. Rarick, Caio Rocha‐Lima, Paul S. Ritch, Emily Chan, Jennifer L. Spratlin, Teresa Macarulla, Elaine McWhirter, Denis Pezet, Mikhail Lichinitser, Laslo Roman, Alan C. Hartford, Kendall Morrison, (unknown), M. Vincent, Leonard Reyno, Manuel Hidalgo	29
5	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology 2013 ·Breast Cancer Research and Treatment ·Sally Garnett, Miguel Martín, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, (unknown), Mikhail Lichinitser, Kelly Pendergrass, Justin P.O. Lindemann, Angelo Di Leo	17
6	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer 2012 ·The Oncologist ·Miguel Martín, А. Н. Махсон, Joseph Gligorov, Mikhail Lichinitser, Aňa Lluch, Semiglazov Vf, Nana Scotto, Lada Mitchell, Sergei Tjulandin	40
7	Klinicheskie rekomendatsii po profilaktikei lecheniyu toshnoty i rvoty u bol'nykh,poluchayushchikh khimio- i luchevuyuprotivoopukholevuyu terapiyu 2011 ·SHILAP Revista de lepidopterología ·I V Poddubnaya, Mikhail Lichinitser, (unknown), (unknown), (unknown), (unknown), (unknown), Л. В. Болотина, (unknown), Oleg Gladkov, Ірина Давиденко, Lyudmila Zhukova, И. А. Королева, (unknown), George Manikhas, (unknown), (unknown), Р. Ш. Хасанов, (unknown)	1
8	First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study 2011 ·Annals of Oncology ·Laura Biganzoli, (unknown), Zefei Jiang, Mikhail Lichinitser, (unknown), R. Delva, Natalia Bogdanova, Guillermo López-Vivanco, (unknown), Ying Cheng, Marianne Just, Marc Espié, J. Vinholes, Caroline Hamm, Diana Crivellari, Ewa Chmielowska, Semiglazov Vf, Florence Dalenc, Ian Smith	44
9	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study breakdown → 2010 ·Journal of Clinical Oncology ·Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun	1102
10	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial breakdown → 2010 ·Journal of Clinical Oncology ·Jaffer A. Ajani, W. Rodriguez, G. Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, В. А. Горбунова, Ihor Vynnychenko, August Garin, István Láng, S. Falcon	425
11	First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial 2010 ·Journal of Clinical Oncology ·Michael Untch, M Muscholl, Sergei Tjulandin, W. Jonat, H.G. Meerpohl, Mikhail Lichinitser, Alexey Manikhas, Alexandra Coumbos, R. Kreienberg, Andreas du Bois, Nadia Harbeck, Christian Jackisch, Volkmar Müller, Matthias Pauschinger, Christoph Thomssen, Michaela Lehle, Olivier Catalani, Hans‐Joachim Lück	55
12	Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial breakdown → 2009 ·Annals of Oncology ·Yoon‐Koo Kang, Won Ki Kang, D.B. Shin, Jingyu Chen, Jianping Xiong, Jie Wang, Mikhail Lichinitser, (unknown), Р. Ш. Хасанов, Leizhen Zheng, (unknown), T. Suarez, Javier Gutiérrez Santamarı́a, Gerhard Förster, P. McCloud	582
13	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study breakdown → 2008 ·Journal of Clinical Oncology ·Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Jim Cassidy	2275
14	Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer 2008 ·Bulletin of Experimental Biology and Medicine ·(unknown), (unknown), (unknown), Mikhail Lichinitser	1
15	B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Andrea Ardizzoni, Evangelia Razis, Mikhail Lichinitser, Uğur Yılmaz, Alexandru Grigorescu, (unknown), Jana Skřičková, Guadalupe Cervantes, Maya Gottfried, Jan P. van Meerbeeck	3
16	Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level 2007 ·Melanoma Research ·А. А. Вартанян, (unknown), Е. В. Степанова, A. Yu. Baryshnikov, Mikhail Lichinitser	28
17	Involvement of Apoptosis in the Formation of Vasculogenic Mimicry in the Malignant Neoplasms 2005 ·Doklady Biological Sciences ·(unknown), Е. В. Степанова, A. Yu. Baryshnikov, Mikhail Lichinitser	2
18	Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patients 2005 ·International Journal of Cancer ·Yuriy V. Shebzukhov, Ekaterina P. Koroleva, (unknown), (unknown), (unknown), (unknown), Fanny Longpré, Maria A. Lagarkova, (unknown), (unknown), Andrey Meshcheryakov, Mikhail Lichinitser, Alexander Knuth, Elke Jäger, Dmitry V. Kuprash, Sergei A. Nedospasov	15
19	[Combination of platidiam and bleomycetin in disseminated skin melanoma]. 1985 ·PubMed ·A. Garin, (unknown), Mikhail Lichinitser, (unknown)	1
20	[Therapeutic use of carminomycin in soft tissue sarcomas]. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Н И Переводчикова, (unknown), Mikhail Lichinitser, Л. В. Мороз	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact